Download PDF
Aktuelle Neurologie 2014; 41(08): 476-490
DOI: 10.1055/s-0034-1387219
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Kinderwunsch und Multiple Sklerose

Family Planning and Multiple Sclerosis
S. Herbstritt
Neurologische Klinik, St. Josef Hospital, Ruhr-Universität Bochum
,
R. Gold
Neurologische Klinik, St. Josef Hospital, Ruhr-Universität Bochum
,
K. Hellwig
Neurologische Klinik, St. Josef Hospital, Ruhr-Universität Bochum
› Author Affiliations
Further Information

Publication History

Publication Date:
13 October 2014 (online)

Also available at
    Permissions and Reprints

Corrected by:

Kinderwunsch und Multiple SkleroseAktuelle Neurologie 2014; 41(08): e95
DOI: 10.1055/s-0033-1337051

See also:

Kinderwunsch und Multiple SkleroseFrauenheilkunde up2date 2015; 9(02): 133-151
DOI: 10.1055/s-0033-1358114

Lernziele

  • Fertilität und unerwünschter Kinderwunsch

  • Diskussion der beidseitigen Wechselwirkung von Multiple Sklerose und Schwangerschaft

  • Diskussion der aktuellen Datenlage zur immunmodulatorischen Therapie für MS-Patienten mit Kinderwunsch

  • Datenlage postpartum

 

  • Literatur

  • 1 Orton SM, Herrera BM, Yee IM et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-936
    CrossrefPubMedGoogle Scholar
  • 2 Cavalla P, Rovei V, Masera S et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006; 27: 231-239
    CrossrefPubMedGoogle Scholar
  • 3 Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler 2010; 16: 950-955
    CrossrefPubMedGoogle Scholar
  • 4 Thöne J, Kollar S, Nousome D, Ellrichmann G, Kleiter I, Gold R, Hellwig K. Serum Anti-Müllerian Hormone Levels in Reproductive-Age Women with Relapsing Remitting Multiple Sclerosis. MSJ accepted 2012. http://www.deutschesapothekenportal.de/fileadmin/bestellungen/fi_betaferon.pdf
    Google Scholar
  • 5 Fachinformation. Betaferon® 250 Mikrogramm/ml. 2012. http://www.deutschesapothekenportal.de/fileadmin/bestellungen/fi_betaferon.pdf
    Google Scholar
  • 6 Cocco E, Sardu C, Gallo P et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233
    CrossrefPubMedGoogle Scholar
  • 7 Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; Oct 3.
    PubMedGoogle Scholar
  • 8 Laplaud DA, Leray E, Barriere P et al. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 2006; 66: 1280-1281
    CrossrefPubMedGoogle Scholar
  • 9 Michel L, Foucher Y, Vukusic S et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012; 83: 796-802
    CrossrefPubMedGoogle Scholar
  • 10 Hellwig K, Beste C, Brune N et al. Increased MS relapse rate during assisted reproduction technique. J Neurol 2008; 255: 592-593
    CrossrefPubMedGoogle Scholar
  • 11 Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol 2013; 149: 219-224
    CrossrefPubMedGoogle Scholar
  • 12 Gold SM, Mohr DC, Huitinga I et al. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol 2005; 26: 644-652
    CrossrefPubMedGoogle Scholar
  • 13 Confavreux C, Hutchinson M, Hours MM et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285-291
    CrossrefPubMedGoogle Scholar
  • 14 Hellwig K, Brune N, Haghikia A et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008; 118: 24-28
    CrossrefPubMedGoogle Scholar
  • 15 Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-392
    CrossrefPubMedGoogle Scholar
  • 16 Schaefer C, Spielmann H, Vetter K, Weber-Schöndorfer C. Arzneimittel in Schwangerschaft und Stillzeit. 8.. vollständig überarbeitete Auflage. München: Elsevier GmbH, Urban & Fischer Verlag; 2012
    Google Scholar
  • 17 Ruffatti A, Marson P, Pengo V et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 2007; 6: 196-202
    CrossrefPubMedGoogle Scholar
  • 18 Matok I, Levy A, Wiznitzer A et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57: 699-705
    CrossrefPubMedGoogle Scholar
  • 19 Vukusic S, Hutchinson M, Hours M et al. and the Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353-1360
    CrossrefPubMedGoogle Scholar
  • 20 Koch M, Uyttenboogaart M, Heersema D et al. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 676-678
    CrossrefPubMedGoogle Scholar
  • 21 D’Hooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 2010; 81: 38-41
    CrossrefPubMedGoogle Scholar
  • 22 Ramagopalan S, Yee I, Byrnes J et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012; 83: 793-795
    CrossrefPubMedGoogle Scholar
  • 23 Airas L, Saraste M, Rinta S et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2008; 151: 235-243
    CrossrefPubMedGoogle Scholar
  • 24 Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 2012; 8: 255-263
    CrossrefPubMedGoogle Scholar
  • 25 van der Kop ML, Pearce MS, Dahlgren L et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011; 70: 41-50
    CrossrefPubMedGoogle Scholar
  • 26 Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65: 1961-1963
    CrossrefPubMedGoogle Scholar
  • 27 Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol 2008; 255: 623-627
    CrossrefPubMedGoogle Scholar
  • 28 Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 2009; 73: 1831-1836
    CrossrefPubMedGoogle Scholar
  • 29 Ellen Lu, Zhao Y, Zhu F et al. On behalf of the British Columbia Multiple Sclerosis Clinic Neurologists. Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology 2013; 80: 447-452
    CrossrefPubMedGoogle Scholar
  • 30 Pastò L, Portaccio E, Ghezzi A et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 2012; 12: 165
    CrossrefPubMedGoogle Scholar
  • 31 Borisow N, Doring A, Pfueller CF et al. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. Epma J 2012; 3: 9
    CrossrefPubMedGoogle Scholar
  • 32 Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013; 260: 1202-1214
    CrossrefPubMedGoogle Scholar
  • 33 Geissbühler YBH, Hernández-Diaz S et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis. Lyon, France: ECTRIMS; 2012 12 Oct; Abstract 751
    PubMedGoogle Scholar
  • 34 Kieseier B, Benamor M, Truffinet P. Pregnancy Outcomes from the Teriflunomide Clinical Development Program Pactrims. 2013 P79
    PubMedGoogle Scholar
  • 35 Briggs GG, Freeman RK, Yaffe SJ. Classification of drugs for teratogenic risk: an anachronistic way of counseling: a reply to Merlob And Stahl. Birth Defects Res A Clin Mol Teratol 2003; 67: 207-208
    CrossrefPubMedGoogle Scholar
  • 36 Lu E, Wang BW, Guimond C et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology 2012; 79: 1130-1135
    CrossrefPubMedGoogle Scholar
  • 37 Amato MP, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010; 75: 1794-1802
    CrossrefPubMedGoogle Scholar
  • 38 Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009; 15: 1037-1042
    CrossrefPubMedGoogle Scholar
  • 39 Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806
    CrossrefPubMedGoogle Scholar
  • 40 Sandberg-Wollheim M, Alteri E, Moraga MS et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011; 17: 423-430
    CrossrefPubMedGoogle Scholar
  • 41 Boskovic R, Wide R, Wolpin J et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807-811
    CrossrefPubMedGoogle Scholar
  • 42 Hellwig K, Haghikia A, Rockhoff M et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5: 247-253
    CrossrefPubMedGoogle Scholar
  • 43 Fragoso YD, Adoni T, Alves-Leon SV et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27: 955-961
    CrossrefPubMedGoogle Scholar
  • 44 Coyle PKJK, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003; 60: A60
    PubMedGoogle Scholar
  • 45 Giannini M, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012; 12: 124
    CrossrefPubMedGoogle Scholar
  • 46 Ebrahimi N, Herbstritt S, Gold R et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective controlled observational study. MSJ accepted 2014;
    PubMedGoogle Scholar
  • 47 Cristiano LBC, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Exposure Registry. ECTRIMS; 2011 P1005
    PubMedGoogle Scholar
  • 48 Fagiu J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand 2014; Feb 15
    PubMedGoogle Scholar
  • 49 Haghikia A, Langer Gould A, Rellensmann G et al. Natalizumab use during third trimester of pregnancy. JAMA Neurol 2014; May 12. DOI: 10.1001/jamaneurol.2014.209.
    PubMedGoogle Scholar
  • 50 Palmeira P, Quinello C, Silveira-Lessa AL et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
    PubMedGoogle Scholar
  • 51 Fachinformation. Gilenya® . Mai 2014
    PubMedGoogle Scholar
  • 52 Karlsson G, Francis G, Koren G et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82: 674-680
    CrossrefPubMedGoogle Scholar
  • 53 Fachinformation. Tecfidera® . April 2014
    PubMedGoogle Scholar
  • 54 Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Novas M, Li J, Sweetser MT, Kurukulasuriya NC, Viglietta V, Fox RJ. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. 66th Annual Meeting of the American Academy of Neurology April 30, Philadelphia, Pennsylvania: 2014
    PubMedGoogle Scholar
  • 55 http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf
  • 56 Fachinformation. AUBAGIO® 14 mg Filmtabletten. November 2013
    PubMedGoogle Scholar
  • 57 Chambers CD, Johnson DL, Robinson LK et al. and the Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62: 1494-1503
    CrossrefPubMedGoogle Scholar
  • 58 Cassina M, Johnson DL, Robinson LK et al. for the Organization of Teratology Information Specialists Collaborative Research Group. Pregnancy Outcome in Women Exposed to Leflunomide Before or During Pregnancy. Arthritis Rheum 2012; 64: 2085-2094
    CrossrefPubMedGoogle Scholar
  • 59 Fachinfo. Lemtrada® 12 mg Konzentrat zur Herstellung einer Infusionslösung. Dezember 2013
    PubMedGoogle Scholar
  • 60 Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012; 38: 266-274
    CrossrefPubMedGoogle Scholar
  • 61 De Santis M, Straface G, Cavaliere AF et al. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology 2007; 28: 696-697
    CrossrefPubMedGoogle Scholar
  • 62 Hellwig K, Schimrigk S, Chan A et al. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 2011; 307: 164-165
    CrossrefPubMedGoogle Scholar
  • 63 Azuno Y, Kaku K, Fujita N. Mitoxantron and etoposid in breastmilk. Am J Hematol 1995; 48: 131-132
    PubMedGoogle Scholar
  • 64 Giacalone PL, Benos P, Rousseau O. Chemotherapy for breast carcinoma during pregnancy. Cancer 1999; 86: 2266-2272
    CrossrefPubMedGoogle Scholar
  • 65 Reynoso EE, Huerta F. Acute leukemia and pregnancy – fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994; 33: 703-716
    CrossrefPubMedGoogle Scholar
  • 66 Cocco E, Sardu C, Gallo P. FEMIMS Group et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233
    CrossrefPubMedGoogle Scholar
  • 67 Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-405
    CrossrefPubMedGoogle Scholar
  • 68 Telez N, Gris J, Tintore M et al. Prevention of persistent ovarian failure after mitoxantrone in women with MS. Design of a treatment protocol with triptorelin. Multiple sclerosis 2006; 12 (Suppl. 01) P 758
    PubMedGoogle Scholar
  • 69 Ericson A, Källén BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001; 15: 371-375
    CrossrefPubMedGoogle Scholar
  • 70 Ratnayaka BD, Dhaliwal H, Watkin S. Neonatal convulsions after withdrawal of baclofen. BMJ 2001; 323: 85
    PubMedGoogle Scholar
  • 71 Moran LR, Almeida PG, Worden S et al. Intrauterine baclofen exposure: a multidisciplinary approach. Pediatrics 2004; 114: e267-269
    CrossrefPubMedGoogle Scholar
  • 72 Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27: 993-1002
    CrossrefPubMedGoogle Scholar
  • 73 Vajda FJ, Hitchcock AA, Graham J et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51: 805-810
    CrossrefPubMedGoogle Scholar
  • 74 Cunnington MC, Weil JG, Messenheimer JA et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76: 1817-1823
    CrossrefPubMedGoogle Scholar
  • 75 Jentink J, Dolk H, Loane MA et al. EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010; 341: c6581
    CrossrefPubMedGoogle Scholar
  • 76 Fujii H, Goel A, Bernard N et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013; 80: 1565-1570
    CrossrefPubMedGoogle Scholar
  • 77 Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-1733
    CrossrefPubMedGoogle Scholar
  • 78 Nordeng H, van Gelder MM, Spigset O et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32: 186-194
    CrossrefPubMedGoogle Scholar
  • 79 Colvin L, Slack-Smith L, Stanley FJ et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91: 142-152
    CrossrefPubMedGoogle Scholar
  • 80 Merlob P, Birk E, Sirota L et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009; 85: 837-841
    CrossrefPubMedGoogle Scholar
  • 81 Hellwig KKM, Gold R, Langer-Gould A. Exclusive breastfeeding reduces the risk of postpartum relapses – a prospective study from the German MS and pregnancy registry: Experience from a nationwide database. Neurology 2011; 76: A272
    PubMedGoogle Scholar
  • 82 Langer-Gould A, Huang SM, Gupta R et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66: 958-963
    CrossrefPubMedGoogle Scholar
  • 83 Portaccio E, Ghezzi A, Hakiki B et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77: 145-150
    CrossrefPubMedGoogle Scholar
  • 84 Airas L, Jalkanen A, Alanen A et al. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 2010; 75: 474-476
    CrossrefPubMedGoogle Scholar
  • 85 Pakpoor J, Disanto G, Lacey MV et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259: 2246-2248
    CrossrefPubMedGoogle Scholar
  • 86 Greenberger PA, Odeh YK, Frederiksen MC et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993; 53: 324-328
    CrossrefPubMedGoogle Scholar
  • 87 Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact 2000; 16: 226-228
    CrossrefPubMedGoogle Scholar
  • 88 Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med 2012; 7: 123-125
    CrossrefPubMedGoogle Scholar
  • 89 de Seze J, Chapelotte M, Delalande S et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10: 596-597
    CrossrefPubMedGoogle Scholar
  • 90 Achiron A, Rotstein Z, Noy S et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25-28
    PubMedGoogle Scholar
  • 91 Achiron A, Kishner I, Dolev M et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251: 1133-1137
    PubMedGoogle Scholar
  • 92 Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 900-908
    CrossrefPubMedGoogle Scholar
  • 93 Portaccio E, Ghezzi A, Hakiki B et al. for the MS Study Group of the Italian Neurological Society. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014; 85: 845-850
    CrossrefPubMedGoogle Scholar
  • 94 Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2010; 257: 580-583
    CrossrefPubMedGoogle Scholar
  • 95 Lu E, Zhu F, Zhao Y et al. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler 2014; Feb 5
    PubMedGoogle Scholar
  • 96 Pecori C, Giannini M, Portaccio E et al. MS Study Group of the Italian Neurological Society. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol 2014; 14: 114
    CrossrefPubMedGoogle Scholar
  • 97 Hanulíková P, Vlk R, Meluzínová E et al. Pregnancy and multiple sclerosis – outcomes analysis 2003-2011. Ceska Gynekol 2013; 78: 142-148
    PubMedGoogle Scholar
  • 98 Hellwig K, Schimrigk S, Beste C et al. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2009; 61: 65-68
    CrossrefPubMedGoogle Scholar
  • 99 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf
  • 100 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf
  • 101 Fachinformation. Copaxone® 20 mg/ml. Mai 2014
    PubMedGoogle Scholar
  • 102 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000603/WC500148205.pdf
  • 103 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf
  • 104 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002601/WC500162070.pdf
  • 105 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002514/WC500148684.pdf
  • 106 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003718/WC500150522.pdf
  • 107 Fachinformation. Ralenova® 2 mg/ml. Januar 2008
    PubMedGoogle Scholar